Abstract: The invention provides a syringe accessory device for adjustment of a predefined partial syringe dosage comprises a recess (10) for receiving a syringe body (14). Additionally, within a single portion (12) a slot (16) is located. Within the slot (16) a syringe flange (18) or finger grip can be held. To obtain a predefined dosage of liquid within the chamber of the syringe body (14), a plunger (26) is pressed in the chamber (14) in the direction of the arrow (38) until the plunger head (44) contacts a stopping means (24) whereby the stopping means is performed by a stopping surface (24) of the single portion (12). The invention further provides a kit comprising said syringe accessory device and its use for adjusting defined liquid dosages in syringes.
Abstract: HCV E1E2 compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or immunostimulatory nucleic acid sequences are described. The compositions can be used in methods of stimulating an immune response in a vertebrate subject.
Type:
Application
Filed:
May 12, 2009
Publication date:
October 15, 2009
Applicant:
Chiron Corporation
Inventors:
Michael Hougton, Stephen R. Coates, Derek O'Hagan, Yiu-Lian Fong
Abstract: A known surface adhesin (NadA) in Neisseria meningitidis contains sequences which correspond to the fusion peptide, HR1 repeat and HR2 repeat seen in the envelope protein of viruses. Fusion inhibitors may thus be used to inhibit meningococcal infection, and the invention provides a compound that can bind to the heptad repeat sequence(s) HR1 and/or HR2 of the NadA adhesin on the surface of a meningococcus, thereby inhibiting the ability of the meningococcus either to infect a host organism or to spread an existing infection.
Type:
Application
Filed:
July 6, 2005
Publication date:
July 9, 2009
Applicant:
CHIRON SRL
Inventors:
Vega Masignani, Rino Rappuoli, Barbara Capecchi, Silvana Savino, Maria Beatrice Arico
Abstract: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.
Type:
Application
Filed:
March 21, 2008
Publication date:
June 4, 2009
Applicant:
CHIRON CORPORATION
Inventors:
Timothy S. Burkoth, Anne B. Jefferson, Christoph Reinhard, Ronald N. Zuckermann
Abstract: The present invention relates to the combination of antigens directed against bacteria and viruses, their uses and the preparation of medicaments in order to confer protection against infectious diseases. In particular, the invention relates to a combination vaccine comprising at least one antigen of Clostridium tetani, at least one antigen from Corynebacterium diphtheriae, and at least one antigen from the TBE-flavivirus suitable to confer seroprotection against diseases and medical conditions caused by these pathogenic organisms.
Abstract: Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus 5 culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.
Abstract: A machine tool comprising at least one machining unit having at least one work spindle for accommodating tools in order to machine workpieces in a working area is provided with a first and a second transport device, by which workpieces are transported between the working area and a loading/unloading station. A second machining unit is arranged laterally next to the first machining unit in such a way that, alternating with the first machining unit, it can reach the workpieces in the working area from the same direction.
Abstract: Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.
Type:
Application
Filed:
August 8, 2008
Publication date:
March 5, 2009
Applicant:
CHIRON CORPORATION
Inventors:
John N. Nuss, Sabina Pecchi, Paul A. Renhowe
Abstract: The present invention relates to methods of predicting the course of malignant disease and more specifically to methods which use SERPINE2 as a prognostic indicator of disease in cancer patients.
Type:
Application
Filed:
June 3, 2004
Publication date:
February 5, 2009
Applicant:
Chiron Corporation
Inventors:
Edward Moler, Filippo Randazzo, Michael Rowe
Abstract: The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
Type:
Application
Filed:
October 14, 2005
Publication date:
December 25, 2008
Applicant:
CHIRON CORPORATION
Inventors:
Rustum S. Boyce, Yi Xia, Hongyan Guo, Kris G. Mendenhall, Annette O. Walter, Weibo Wang
Abstract: The invention is based on the use of solid phase extraction for separating conjugated saccharide from unconjugated saccharide in sample, e.g. a vaccine. Solid phase extraction (SPE) provides faster and more reproducible separation of conjugated saccharides from unconjugated saccharides, thereby allowing quantitative separation of these saccharides. The separation of conjugated and unconjugated saccharide using SPE may be advantageously combined with a quantitative conjugate analysis to provide improved quality control for conjugate vaccines. The SPE separation is compatible with existing quantitative conjugate analysis techniques, such as high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD).
Abstract: The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers).
Abstract: Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.
Abstract: The degree of polymerisation (DP) is an important parameter for analysis of saccharide antigens, particularly in glycoconjugates. The invention provides methods that can be used to measure DP for capsular saccharides, particularly for meningococcal saccharides e.g. from serogroups W135 and Y. A preferred method is based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid.
Abstract: The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable of neutralising said human influenza virus strain. Whereas the prior art used known non-pathogenic avian strains to generate antibodies in humans against known pathogenic avian strains, the invention uses known pathogenic avian strains to protect against emerging pathogenic human strains. Furthermore, whereas the prior art focused on achieving a close antigenic match between the vaccine strain and the target strain, the invention selects vaccine strains based on their pathogenicity, regardless of any perceived close antigenic relationship to the target strain.
Type:
Application
Filed:
March 9, 2005
Publication date:
October 16, 2008
Applicant:
CHIRON CORPORATION
Inventors:
Audino Podda, Olga Popova, Francesca Piccinetti
Abstract: The present invention relates to compounds that are useful for treating cellular proliferative diseases, for treating disorders mediated, at least in part, by KSP, and for inhibiting KSP. The invention also related to pharmaceutical compositions comprising such compounds, methods of treating cancer by the administration of such compositions, and processes for the preparation of the compounds. Compounds of the invention have the following formula: formula (I).
Type:
Application
Filed:
April 6, 2005
Publication date:
October 9, 2008
Applicant:
CHIRON CORPORATION
Inventors:
Weibo Wang, Ryan N. Constantine, Liana M. Lagniton
Abstract: Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.
Type:
Grant
Filed:
November 21, 2003
Date of Patent:
September 9, 2008
Assignee:
Chiron Corporation
Inventors:
John N. Nuss, Sabina Pecchi, Paul A. Renhowe
Abstract: A machine tool is provided with at least one tool spindle which is travelling in a work space (11) and on which a tool receptacle for clamping tools is provided. The machine tool also contains a magazine for tools which can be introduced into the tool receptacle in the tool spindle, the magazine having a transport chain which can be moved back and forth in a transport direction and on which carriers are arranged for receiving tools. The carriers extend from the transport chain essentially transversely to the transport direction. At least one carrier has at least two storage spaces for tools.
Abstract: A machine tool center (10) displays at least one machine tool (11, 12, 13) which has a working area (17) accessible through an operator door (16) to process workpieces (21). Furthermore, a loading/unloading station (14) for the workpieces (21) and a loading device (22) which transports the workpieces (21) between the loading/unloading station (14) and the respective machine tool (11, 12, 13) and changes these at the machine tool (11, 12, 13) are also provided. In the new machine tool center (10) the loading device (22) is arranged below the working space (17) of the machine tool (11, 12, 13) (FIG. 1).